Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Life Cycle and in silico Elucidation of Non-structural Replicating Proteins of HCV Through a Pharmacoinformatics Approach

Author(s): Rana Adnan Tahir, Sumera Mughal, Amina Nazir, Asma Noureen, Ayesha Jawad, Muhammad Waqas and Sheikh Arslan Sehgal*

Volume 25, Issue 4, 2022

Published on: 17 February, 2021

Page: [689 - 701] Pages: 13

DOI: 10.2174/1386207324666210217144306

Price: $65

Abstract

Background: Hepatitis C virus (HCV) is an enveloped and positive-stranded RNA virus that is a major causative agent of chronic liver diseases worldwide. HCV has become the main cause of liver transplantations and there is no effective drug for all hepatitis genotypes. Elucidation of the life cycle and non-structural proteins of HCV, involved in viral replication, are attractive targets for the development of antiviral drugs..

Methods: In this work, pharmacoinformatics approaches coupled with docking analyses were applied on HCV non-structural proteins to identify the novel potential hits and HCV drugs. Molecular docking analyses were carried out on HCV-approved drugs, followed by the ligandbased pharmacophore generation to screen the antiviral libraries for novel potential hits.

Results: Virtual screening technique has top-ranked five novel compounds (ZINC00607900, ZINC03635748, ZINC03875543, ZINC04097464, and ZINC12503102) along with their least binding energies (-8.0 kcal/mol, -6.1 kcal/mol, -7.5 kcal/mol, -7.4 kcal/mol, and -7.3 kcal/mol, respectively) and stability with the non-structural proteins target.

Conclusion: These promising hits exhibited better absorption and ADMET properties as compared to the selected drug molecules. These potential compounds extracted from in silico approach may be significant in drug design and development against Hepatitis and other liver diseases.

Keywords: Hepatitis, HCV, NS proteins, pharmacoinformatics, molecular docking, HCV life cycle.

« Previous Next »
Graphical Abstract

[1]
Bradley, D.W.; McCaustland, K.A.; Cook, E.; Schable, C.A.; Ebert, J.W.; Maynard, J.E. Posttransfusion non-A, non-B hepatitis in chimpanzees: physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology, 1985, 88(3), 773-779.
[2]
Gastaminza, P.; Dryden, K.A.; Boyd, B.; Wood, M.R.; Law, M.; Yeager, M.; Chisari, F.V. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. Journal of Virology, 2010, 84(21), 10999-11009.
[3]
Popescu, C-I.; Riva, L.; Vlaicu, O.; Farhat, R.; Rouillé, Y.; Dubuisson, J. Hepatitis C virus life cycle and lipid metabolism. Biology, 2014, 3(4), 892-921.
[4]
Stambouli, O. 2014.
[5]
Colpitts, C.C.; Baumert, T.F. SMAD About Hepatitis C Virus Cell Entry and Liver Disease. Gastroenterology, 2017, 152(1), 21.
[6]
Boyer, A.; Dumans, A.; Beaumont, E.; Etienne, L.; Roingeard, P.; Meunier, J-C. The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. Journal of Biological Chemistry, 2014, 289(27), 18904-18913.
[7]
Lee, J-Y.; Acosta, E.G.; Stoeck, I.K.; Long, G.; Hiet, M-S.; Mueller, B.; Fackler, O.T.; Kallis, S.; Bartenschlager, R. Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins. Journal of virology, 2014, 88(21), 12422-12437.
[8]
Albecka, A.; Belouzard, S.; de Beeck, A.O.; Descamps, V.; Goueslain, L.; Bertrand‐Michel, J.; Tercé, F.; Duverlie, G.; Rouillé, Y.; Dubuisson, J. Role of low‐density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology, 2012, 55(4), 998-1007.
[9]
Thi, V.L.D.; Granier, C.; Zeisel, M.B.; Guérin, M.; Mancip, J.; Granio, O.; Penin, F.; Lavillette, D.; Bartenschlager, R.; Baumert, T.F. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. Journal of Biological Chemistry, 2012, 287(37), 31242-31257.
[10]
Zahid, M.N.; Turek, M.; Xiao, F.; Dao Thi, V.L.; Guérin, M.; Fofana, I.; Bachellier, P.; Thompson, J.; Delang, L.; Neyts, J. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology, 2013, 57(2), 492-504.
[11]
Scarselli, E.; Ansuini, H.; Cerino, R.; Roccasecca, R.M.; Acali, S.; Filocamo, G.; Traboni, C.; Nicosia, A.; Cortese, R.; Vitelli, A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. The EMBO journal, 2002, 21(19), 5017-5025.
[12]
Bankwitz, D.; Steinmann, E.; Bitzegeio, J.; Ciesek, S.; Friesland, M.; Herrmann, E.; Zeisel, M.B.; Baumert, T.F.; Keck, Z-y.; Foung, S.K. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. Journal of virology, 2010, 84(11), 5751-5763.
[13]
Farquhar, M.J.; Hu, K.; Harris, H.J.; Davis, C.; Brimacombe, C.L.; Fletcher, S.J.; Baumert, T.F.; Rappoport, J.Z.; Balfe, P.; McKeating, J.A. Hepatitis C virus induces CD81 and claudin-1 endocytosis. Journal of virology, 2012, 86(8), 4305-4316.
[14]
Kim, C.W.; Chang, K-M. Hepatitis C virus: virology and life cycle. Clinical and molecular hepatology, 2013, 19(1), 17.
[15]
Lescar, J.; Roussel, A.; Wien, M.W.; Navaza, J.; Fuller, S.D.; Wengler, G.; Wengler, G.; Rey, F.A. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell, 2001, 105(1), 137-148.
[16]
Jackson, R.J.; Kaminski, A. Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA, 1995, 1(10), 985.
[17]
Friebe, P.; Lohmann, V.; Krieger, N.; Bartenschlager, R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. Journal of virology, 2001, 75(24), 12047-12057.
[18]
Luo, G.; Xin, S.; Cai, Z. Role of the 5′-proximal stem-loop structure of the 5′ untranslated region in replication and translation of hepatitis C virus RNA. Journal of virology, 2003, 77(5), 3312-3318.
[19]
Niepmann, M. In Hepatitis C Virus: From Molecular Virology to Antiviral Therapy; Springer, 2013, pp. 143-166.
[20]
Honda, M.; Ping, L-H.; Rijnbrand, R.C.; Amphlett, E.; Clarke, B.; Rowlands, D.; Lemon, S.M. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology, 1996, 222(1), 31-42.
[21]
Romero-López, C.; Berzal-Herranz, A. Structure-function relationship in viral RNA genomes: The case of hepatitis C virus. 2014.
[22]
Jopling, C.L.; Yi, M.; Lancaster, A.M.; Lemon, S.M.; Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liverspecific MicroRNA. science, 2005, 309(5740), 1577-1581.
[23]
Moradpour, D.; Bieck, E.; Hügle, T.; Wels, W.; Wu, J.Z.; Hong, Z.; Blum, H.E.; Bartenschlager, R. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. Journal of Biological Chemistry, 2002, 277(1), 593-601.
[24]
Carrère-Kremer, S.; Montpellier, C.; Lorenzo, L.; Brulin, B.; Cocquerel, L.; Belouzard, S.; Penin, F.; Dubuisson, J. Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. Journal of Biological Chemistry, 2004, 279(40), 41384-41392.
[25]
Roingeard, P.; Hourioux, C.; Blanchard, E.; Brand, D.; Ait‐Goughoulte, M. Hepatitis C virus ultrastructure and morphogenesis. Biology of the Cell, 2004, 96(2), 103-108.
[26]
Tomei, L.; Failla, C.; Santolini, E.; De Francesco, R.; La Monica, N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. Journal of virology, 1993, 67(7), 4017-4026.
[27]
Egger, D.; Wölk, B.; Gosert, R.; Bianchi, L.; Blum, H.E.; Moradpour, D.; Bienz, K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. Journal of virology, 2002, 76(12), 5974-5984.
[28]
Gosert, R.; Egger, D.; Lohmann, V.; Bartenschlager, R.; Blum, H.E.; Bienz, K.; Moradpour, D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. Journal of virology, 2003, 77(9), 5487-5492.
[29]
Alvisi, G.; Madan, V.; Bartenschlager, R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol., 2011, 8(2), 258-269.
[30]
Bartenschlager, R.; Cosset, F-L.; Lohmann, V. Hepatitis C virus replication cycle. Journal of hepatology, 2010, 53(3), 583-585.
[31]
Romero-Brey, I.; Merz, A.; Chiramel, A.; Lee, J-Y.; Chlanda, P.; Haselman, U.; Santarella-Mellwig, R.; Habermann, A.; Hoppe, S.; Kallis, S. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS pathogens, 2012, 8(12), e1003056.
[32]
Bartenschlager, R.; Frese, M.; Pietschmann, T. Novel insights into hepatitis C virus replication and persistence. Advances in virus research, 2004, 63, 72-181.
[33]
Miyanari, Y.; Atsuzawa, K.; Usuda, N.; Watashi, K.; Hishiki, T.; Zayas, M.; Bartenschlager, R.; Wakita, T.; Hijikata, M.; Shimotohno, K. The lipid droplet is an important organelle for hepatitis C virus production. Nature cell biology, 2007, 9(9), 1089.
[34]
Moradpour, D.; Gosert, R.; Egger, D.; Penin, F.; Blum, H.E.; Bienz, K. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral research, 2003, 60(2), 103-109.
[35]
Madan, V.; Paul, D.; Lohmann, V.; Bartenschlager, R. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology, 2014, 146(5), 1361-1372. e1369.
[36]
Moradpour, D. Penin, F. In: Hepatitis C virus: from molecular virology to antiviral therapy; Springer, 2013; pp. 113-142.
[37]
Asabe, S-I.; Tanji, Y.; Satoh, S.; Kaneko, T.; Kimura, K.; Shimotohno, K. The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. Journal of Virology, 1997, 71(1), 790-796.
[38]
Pang, P.S.; Jankowsky, E.; Planet, P.J.; Pyle, A.M. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. The EMBO journal, 2002, 21(5), 1168-1176.
[39]
Hügle, T.; Fehrmann, F.; Bieck, E.; Kohara, M.; Kräusslich, H-G.; Rice, C.M.; Blum, H.E.; Moradpour, D. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Journal of virology, 2001, 284(1), 70-81.
[40]
Lin, C.; Wu, J-W.; Hsiao, K.; Su, M. The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins. Journal of virology, 1997, 71(9), 6465-6471.
[41]
Jones, D.M.; Patel, A.H.; Targett-Adams, P.; McLauchlan, J. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. Journal of virology, 2009, 83(5), 2163-2177.
[42]
Paul, D.; Romero-Brey, I.; Gouttenoire, J.; Stoitsova, S.; Krijnse-Locker, J.; Moradpour, D.; Bartenschlager, R. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. Journal of virology, 2011, 85(14), 6963-6976.
[43]
Appel, N.; Zayas, M.; Miller, S.; Krijnse-Locker, J.; Schaller, T.; Friebe, P.; Kallis, S.; Engel, U.; Bartenschlager, R. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS pathogens, 2008, 4(3), e1000035.
[44]
Kim, S.; Welsch, C.; Yi, M.; Lemon, S.M. Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III. Journal of virology, 2011, 85(13), 6645-6656.
[45]
Neddermann, P.; Clementi, A.; De Francesco, R. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. Journal of virology, 1999, 73(12), 9984-9991.
[46]
Lohmann, V.; Körner, F.; Koch, J-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285(5424), 110-113.
[47]
Shi, S.T.; Polyak, S.J.; Tu, H.; Taylor, D.R.; Gretch, D.R.; Lai, M.M. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology, 2002, 292(2), 198-210.
[48]
Gale, Jr M.J.; Korth, M.J.; Tang, N.M.; Tan, S-L.; Hopkins, D.A.; Dever, T.E.; Polyak, S.J.; Gretch, D.R.; Katze, M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology, 1997, 230(2), 217-227.
[49]
Shirota, Y.; Luo, H.; Qin, W.; Kaneko, S.; Yamashita, T.; Kobayashi, K.; Murakami, S. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. Journal of Biological Chemistry, 2002, 277(13), 11149-11155.
[50]
Quezada, E.M.; Kane, C.M. The stimulatory mechanism of hepatitis C virus NS5A protein on the NS5B catalyzed replication reaction in vitro. The open biochemistry journal, 2013, 7, 11.
[51]
She, Y.; Liao, Q.; Chen, X.; Ye, L.; Wu, Z. Hepatitis C virus (HCV) NS2 protein up-regulates HCV IRES-dependent translation and down-regulates NS5B RdRp activity. Arch. Virol., 2008, 153(11), 1991-1997.
[52]
Yamashita, T.; Kaneko, S.; Shirota, Y.; Qin, W.; Nomura, T.; Kobayashi, K.; Murakami, S. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem., 1998, 273(25), 15479-15486.
[53]
Huang, J-T.; Tseng, C-P.; Liao, M-H.; Lu, S-C.; Yeh, W-Z.; Sakamoto, N.; Chen, C-M.; Cheng, J-C. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase. J. Virol., 2013, 87(9), 4994-5004.
[54]
De Francesco, R.; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature, 2005, 436(7053), 953.
[55]
Lee, H.; Shin, H.; Wimmer, E.; Paul, A.V. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome. J. Virol., 2004, 78(20), 10865-10877.
[56]
Martell, M.; Esteban, J.I.; Quer, J.; Genesca, J.; Weiner, A.; Esteban, R.; Guardia, J.; Gomez, J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol., 1992, 66(5), 3225-3229.
[57]
Yang, F.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kenworthy, R.; Tang, H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol., 2008, 82(11), 5269-5278.
[58]
Foster, T.L.; Gallay, P.; Stonehouse, N.J.; Harris, M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol., 2011, 85(14), 7460-7464.
[59]
Berger, K.L.; Cooper, J.D.; Heaton, N.S.; Yoon, R.; Oakland, T.E.; Jordan, T.X.; Mateu, G.; Grakoui, A.; Randall, G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. USA, 2009, 106(18), 7577-7582.
[60]
Reiss, S.; Rebhan, I.; Backes, P.; Romero-Brey, I.; Erfle, H.; Matula, P.; Kaderali, L.; Poenisch, M.; Blankenburg, H.; Hiet, M-S. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe, 2011, 9(1), 32-45.
[61]
Tu, H.; Gao, L.; Shi, S.T.; Taylor, D.R.; Yang, T.; Mircheff, A.K.; Wen, Y.; Gorbalenya, A.E.; Hwang, S.B.; Lai, M.M. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology, 1999, 263(1), 30-41.
[62]
Appel, N.; Schaller, T.; Penin, F.; Bartenschlager, R. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem., 2006, 281(15), 9833-9836.
[63]
Hamamoto, I.; Nishimura, Y.; Okamoto, T.; Aizaki, H.; Liu, M.; Mori, Y.; Abe, T.; Suzuki, T.; Lai, M.M.; Miyamura, T. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J. Virol., 2005, 79(21), 13473-13482.
[64]
Masaki, T.; Suzuki, R.; Murakami, K.; Aizaki, H.; Ishii, K.; Murayama, A.; Date, T.; Matsuura, Y.; Miyamura, T.; Wakita, T. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol., 2008, 82(16), 7964-7976.
[65]
Herker, E.; Harris, C.; Hernandez, C.; Carpentier, A.; Kaehlcke, K.; Rosenberg, A.R.; Farese, R.V., Jr; Ott, M. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat. Med., 2010, 16(11), 1295.
[66]
Vogt, D.A.; Camus, G.; Herker, E.; Webster, B.R.; Tsou, C-L.; Greene, W.C.; Yen, T-S.B.; Ott, M. Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. PLoS Pathog., 2013, 9(4), e1003302.
[67]
Clément, S.; Fauvelle, C.; Branche, E.; Kaddai, V.; Conzelmann, S.; Boldanova, T.; Bartosch, B.; Minehira, K.; Negro, F. Role of seipin in lipid droplet morphology and hepatitis C virus life cycle. J. Gen. Virol., 2013, 94(10), 2208-2214.
[68]
Popescu, C-I.; Callens, N.; Trinel, D.; Roingeard, P.; Moradpour, D.; Descamps, V.; Duverlie, G.; Penin, F.; Héliot, L.; Rouille, Y. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog., 2011, 7(2), e1001278.
[69]
Wozniak, A.L.; Griffin, S.; Rowlands, D.; Harris, M.; Yi, M.; Lemon, S.M.; Weinman, S.A. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog., 2010, 6(9), e1001087.
[70]
Sklan, E.H.; Charuworn, P.; Pang, P.S.; Glenn, J.S. Mechanisms of HCV survival in the host. Nat. Rev. Gastroenterol. Hepatol., 2009, 6(4), 217.
[71]
Gastaminza, P.; Kapadia, S.B.; Chisari, F.V. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol., 2006, 80(22), 11074-11081.
[72]
Paul, D.; Madan, V.; Bartenschlager, R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe, 2014, 16(5), 569-579.
[73]
Tahir, R.A.; Sehgal, S.A.; Khattak, N.A.; Khattak, J.Z.K.; Mir, A. Tumor necrosis factor receptor superfamily 10B (TNFRSF10B): an insight from structure modeling to virtual screening for designing drug against head and neck cancer. Theor. Biol. Med. Model., 2013, 10(1), 38.
[74]
Sehgal, S.; Tahir, R.; Shafique, S.; Hassan, M.; Rashid, S. Molecular modeling and docking analysis of CYP1A1 associated with head and neck cancer to explore its binding regions. J Theor Comput Sci, 2014, 1(112), 2.
[75]
Tahir, R.A.; Sehgal, S.A. Pharmacoinformatics and Molecular Docking Studies Reveal Potential Novel Compounds Against Schizophrenia by Target SYN II. Comb. Chem. High Throughput Screen., 2018, 21(3), 175-181.
[76]
Tahir, R.A.; Wu, H.; Javed, N.; Khalique, A.; Khan, S.A.F.; Mir, A.; Ahmed, M.S.; Barreto, G.E.; Qing, H.; Ashraf, G.M.; Sehgal, S.A. Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. J. Cell. Physiol., 2019, 234(8), 13263-13276.
[77]
Sehgal, S.A. Pharmacoinformatics, adaptive evolution, and elucidation of six novel compounds for schizophrenia treatment by targeting DAOA (G72) isoforms. BioMed research international, 2017, 2017
[78]
Tahir, R.A.; Wu, H.; Rizwan, M.A.; Jafar, T.H.; Saleem, S.; Sehgal, S.A. Immunoinformatics and molecular docking studies reveal potential epitope-based peptide vaccine against DENV-NS3 protein. J. Theor. Biol., 2018, 459, 162-170.
[79]
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. Nucleic Acids Res., 2000, 28(1), 235-242.
[80]
Gouttenoire, J.; Montserret, R.; Paul, D.; Castillo, R.; Meister, S.; Bartenschlager, R.; Penin, F.; Moradpour, D. Aminoterminal amphipathic α-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production. PLoS Pathog., 2014, 10(11), e1004501.
[81]
Love, R.A.; Brodsky, O.; Hickey, M.J.; Wells, P.A.; Cronin, C.N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol., 2009, 83(9), 4395-4403.
[82]
LaPlante, S.R.; Gillard, J.R.; Jakalian, A.; Aubry, N.; Coulombe, R.; Brochu, C.; Tsantrizos, Y.S.; Poirier, M.; Kukolj, G.; Beaulieu, P.L. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B. J. Am. Chem. Soc., 2010, 132(43), 15204-15212.
[83]
Mendelsohn, L.D. ChemDraw 8 ultra, windows and macintosh versions. J. Chem. Inf. Comput. Sci., 2004, 44(6), 2225-2226.
[84]
Ultra, C. 6.0 and Chem3D Ultra; Cambridge Soft Corporation: Cambridge, USA, 2001.
[85]
Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25(13), 1605-1612.
[86]
Kiss, R.; Sandor, M.; Szalai, F.A. a public web service for drug discovery. Journal of cheminformatics, 2012, 4(S1), 17.http://Mcule. com
[87]
Jarrahpour, A.; Fathi, J.; Mimouni, M.; Hadda, T.B.; Sheikh, J.; Chohan, Z.; Parvez, A. Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med. Chem. Res., 2012, 21(8), 1984-1990.
[88]
Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, P.W.; Tang, Y. ACS Publications 2012.
[89]
Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45(1), 160-169.
[90]
Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 2010, 31(2), 455-461.
[91]
Shepard, C.W.; Finelli, L.; Alter, M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 2005, 5(9), 558-567.
[92]
Gentile, I.; Buonomo, A.R.; Borgia, F.; Zappulo, E.; Castaldo, G.; Borgia, G. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin. Investig. Drugs, 2014, 23(5), 719-728.
[93]
Bell, A.M.; Wagner, J.L.; Barber, K.E.; Stover, K.R. Elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis C. International journal of hepatology, 2016.2016,
[94]
Kumari, R.; Nguyen, M.H. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin. Pharmacother., 2015, 16(5), 739-748.
[95]
Shen, J.; Serby, M.; Surber, B.; Lee, A.J.; Ma, J.; Badri, P.; Menon, R.; Kavetskaia, O.; de Morais, S.M.; Sydor, J. Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab. Dispos., 2016, 44(8), 1148-1157.
[96]
Klibanov, O.M.; Gale, S.E.; Santevecchi, B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann. Pharmacother., 2015, 49(5), 566-581.

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy